• Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Disease

Donanemab is not a cure and comes with significant side effects, but patients had longer periods of independent living while on the drug.

Gina Kolata
Author: Gina Kolata

Written by

Gina Kolata

in

Drugs (Pharmaceuticals), Eli Lilly and Company, Research
←FTC Seeks ‘Blanket’ Ban on Meta’s Use of Young Users’ Data
Trump’s New Anti-Biden Ad Has One Problem: It Shows Photos From His Own Presidency→

More posts

  • ‘Already won’ or ‘got to finish the job’: Trump’s mixed messages on Iran

  • How Recovery Scams Retarget Victims of Fraud

  • ‘A Lot of Life Years Lost’: How NAFTA Shortened American Life Spans

  • ‘This place broke something in us’: Kids languish in ICE detention long past 20-day limit

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube